Ivabradine Viatris (Ivabradine Oxalate)

Ivabradine acts on the cardiac sinus node to lower heart rate, benefiting conditions where heart‑rate reduction improves outcomes.

• Chronic stable angina pectoris: decreases the frequency of angina attacks by lowering myocardial oxygen demand.
• Heart failure with reduced ejection fraction: improves symptoms and reduces hospitalization when added to standard heart‑failure therapy.

• Ivabradine selectively inhibits the funny (If) current in the sino‑atrial node, which controls spontaneous depolarization. By blocking this channel, the drug slows the pacemaker activity, leading to a reduction in heart rate without affecting myocardial contractility or systemic blood pressure, thereby decreasing cardiac workload.

Ivabradine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Bradycardia: resting heart rate may fall below the desired range.
• Visual disturbances (phosphenes): transient luminous phenomena.
• Headache: mild to moderate intensity.
• Dizziness or vertigo: especially on standing.
• Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

• Severe bradycardia requiring medical intervention.
• Atrial fibrillation or other arrhythmias.
• Symptomatic heart block.
• Persistent visual disturbances affecting daily activities.

Before initiating therapy, clinicians should consider several safety measures.

• Monitor heart rate: ensure resting heart rate is above 60 bpm before starting.
• Avoid in severe hepatic impairment: drug clearance may be reduced.
• Caution in sick‑sinus syndrome: risk of excessive bradycardia.
• Do not combine with strong CYP3A4 inhibitors: may increase plasma levels.
• Store at ambient temperature (below 25°C): keep in the original pack, protect from moisture.

Ivabradine can interact with other medicines, necessitating careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ivabradine concentrations.
• Other bradycardic agents (beta‑blockers, diltiazem, verapamil): risk of excessive heart‑rate reduction.
• Certain anti‑arrhythmic drugs (e.g., amiodarone): can potentiate cardiac conduction effects.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole): may require dose adjustment.
• Drugs affecting electrolyte balance (e.g., diuretics): monitor for arrhythmia risk.